title: Adhesion reduction agents in gynaecological procedures: can NHS aff ord it? An economic cost efficiency analysis.
abstract: We examined the total costs to the National Health Service (NHS, UK) paid to treat adhesion complications and determine the theoretical savings and cost-effectiveness incurred if anti-adhesion agents were adopted. Using Healthcare Resource Groups (HRG) codes, we calculated the costs incurred through Payment by Results (PbR) and then calculated the financial savings that could be realised through the use of anti-adhesion agents. There were 62,186 adhesion-related consultant episodes between 2004 and 2008 encountered within the NHS. If an anti-adhesion agent cost £110 per usage, and can reduce adhesions in 25% of patients undergoing surgery, assuming that 25% of patients were readmitted in the first year after the primary surgery, the financial cost to the health service is, at best, savings of more than £700,000 and at worst, cost neutral to the NHS.
authors.affiliation: University of Southampton Faculty of Medicine, Princess Anne Hospital, Southampton, UK. y.cheong@soton.ac.uk
authors.forename: Y
authors.initials: Y
authors.lastname: Cheong
authors.forename: K
authors.initials: K
authors.lastname: Sadek
authors.forename: A
authors.initials: A
authors.lastname: Watson
authors.forename: M
authors.initials: M
authors.lastname: Metwally
authors.forename: T C
authors.initials: TC
authors.lastname: Li
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000009:adverse effects*; D006801:Humans; D009313:National Health Programs; D012051:Reimbursement Mechanisms; D013222:State Medicine; D000267:Tissue Adhesions / Q000188:drug therapy* / Q000191:economics*; D006113:United Kingdom